Xponance Inc. Takes $50,000 Position in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD)

Xponance Inc. acquired a new position in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 11,310 shares of the biotechnology company’s stock, valued at approximately $50,000.

A number of other large investors have also modified their holdings of the company. Intech Investment Management LLC grew its position in Ironwood Pharmaceuticals by 30.0% in the 4th quarter. Intech Investment Management LLC now owns 57,244 shares of the biotechnology company’s stock worth $254,000 after purchasing an additional 13,205 shares during the last quarter. Cibc World Markets Corp bought a new position in Ironwood Pharmaceuticals in the 4th quarter worth approximately $59,000. Royce & Associates LP increased its position in Ironwood Pharmaceuticals by 10.9% in the 4th quarter. Royce & Associates LP now owns 735,436 shares of the biotechnology company’s stock valued at $3,258,000 after acquiring an additional 72,502 shares during the period. Catalyst Funds Management Pty Ltd bought a new stake in Ironwood Pharmaceuticals during the 4th quarter valued at $47,000. Finally, Swiss National Bank boosted its position in Ironwood Pharmaceuticals by 2.2% during the 4th quarter. Swiss National Bank now owns 282,700 shares of the biotechnology company’s stock worth $1,252,000 after acquiring an additional 6,000 shares during the period.

Ironwood Pharmaceuticals Trading Down 3.4 %

Shares of NASDAQ IRWD opened at $1.41 on Friday. Ironwood Pharmaceuticals, Inc. has a twelve month low of $1.34 and a twelve month high of $8.64. The firm has a 50-day moving average of $2.04 and a two-hundred day moving average of $3.38. The company has a market capitalization of $225.64 million, a price-to-earnings ratio of -47.00 and a beta of 0.37.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last released its earnings results on Thursday, February 27th. The biotechnology company reported $0.02 EPS for the quarter, missing the consensus estimate of $0.10 by ($0.08). The business had revenue of $90.55 million for the quarter, compared to analyst estimates of $93.85 million. Ironwood Pharmaceuticals had a negative net margin of 0.65% and a negative return on equity of 0.96%. As a group, research analysts predict that Ironwood Pharmaceuticals, Inc. will post 0.1 earnings per share for the current year.

Insider Activity

In other news, CEO Thomas A. Mccourt sold 139,064 shares of the business’s stock in a transaction that occurred on Monday, February 10th. The shares were sold at an average price of $1.76, for a total transaction of $244,752.64. Following the sale, the chief executive officer now owns 1,160,634 shares in the company, valued at $2,042,715.84. The trade was a 10.70 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CMO Michael Shetzline sold 41,269 shares of the company’s stock in a transaction that occurred on Monday, February 10th. The shares were sold at an average price of $1.76, for a total transaction of $72,633.44. Following the completion of the sale, the chief marketing officer now owns 554,007 shares of the company’s stock, valued at approximately $975,052.32. This trade represents a 6.93 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 192,381 shares of company stock worth $338,591. Insiders own 12.90% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on the stock. Craig Hallum cut their price objective on shares of Ironwood Pharmaceuticals from $10.00 to $8.00 and set a “buy” rating on the stock in a research note on Wednesday, January 22nd. JMP Securities dropped their price target on shares of Ironwood Pharmaceuticals from $23.00 to $14.00 and set a “market outperform” rating on the stock in a research report on Thursday, January 30th. Finally, StockNews.com upgraded shares of Ironwood Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Saturday. Three analysts have rated the stock with a hold rating and four have given a buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $8.60.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.